CN1167703C - 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 - Google Patents

氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 Download PDF

Info

Publication number
CN1167703C
CN1167703C CNB01808821XA CN01808821A CN1167703C CN 1167703 C CN1167703 C CN 1167703C CN B01808821X A CNB01808821X A CN B01808821XA CN 01808821 A CN01808821 A CN 01808821A CN 1167703 C CN1167703 C CN 1167703C
Authority
CN
China
Prior art keywords
compound
formula
hydrochloride
free base
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB01808821XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1427840A (zh
Inventor
�����ᡤJ������ŵ
J·诺祖拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1427840A publication Critical patent/CN1427840A/zh
Application granted granted Critical
Publication of CN1167703C publication Critical patent/CN1167703C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB01808821XA 2000-05-05 2001-05-03 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 Expired - Fee Related CN1167703C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0010955.3 2000-05-05
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds

Publications (2)

Publication Number Publication Date
CN1427840A CN1427840A (zh) 2003-07-02
CN1167703C true CN1167703C (zh) 2004-09-22

Family

ID=9891092

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB01808821XA Expired - Fee Related CN1167703C (zh) 2000-05-05 2001-05-03 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途

Country Status (29)

Country Link
US (1) US6780861B2 (https=)
EP (1) EP1282620B1 (https=)
JP (1) JP4898062B2 (https=)
KR (1) KR20020093974A (https=)
CN (1) CN1167703C (https=)
AR (1) AR028073A1 (https=)
AT (1) ATE263167T1 (https=)
AU (2) AU2001262257B2 (https=)
BR (1) BR0110521A (https=)
CA (1) CA2407972C (https=)
CZ (1) CZ20023622A3 (https=)
DE (1) DE60102581T2 (https=)
DK (1) DK1282620T3 (https=)
ES (1) ES2218418T3 (https=)
GB (1) GB0010955D0 (https=)
HK (1) HK1054223B (https=)
HU (1) HUP0301866A2 (https=)
IL (1) IL152417A0 (https=)
MX (1) MXPA02010892A (https=)
NO (1) NO20025280D0 (https=)
NZ (1) NZ522226A (https=)
PE (1) PE20020221A1 (https=)
PL (1) PL357435A1 (https=)
PT (1) PT1282620E (https=)
RU (1) RU2002131886A (https=)
SK (1) SK15612002A3 (https=)
TR (1) TR200401007T4 (https=)
WO (1) WO2001085727A1 (https=)
ZA (1) ZA200208969B (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
BR0213501A (pt) * 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP1480977A2 (en) * 2002-02-15 2004-12-01 PHARMACIA & UPJOHN COMPANY Substituted aryl compounds for treatment of disease
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) * 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
JP4750421B2 (ja) 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004085433A2 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
RU2389729C2 (ru) * 2003-12-22 2010-05-20 Мемори Фармасьютиклз Корпорейшн 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
DE602005015682D1 (de) 2004-02-04 2009-09-10 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CA2567977A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
NZ551712A (en) * 2004-05-07 2010-07-30 Memory Pharm Corp 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2591817A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
LT2889033T (lt) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
EP2959902A1 (en) * 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
CN102823159A (zh) * 2010-03-26 2012-12-12 康宁股份有限公司 低非线性长距离光传输系统
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
BR112013001939A2 (pt) 2010-07-26 2017-07-11 Envivo Pharmaceuticals Inc tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
CA2834467A1 (en) * 2011-04-29 2012-11-01 Chiesi Farmaceutici S.P.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
ES2776996T3 (es) * 2011-10-20 2020-08-03 Novartis Ag Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN104837499B (zh) 2012-12-11 2018-02-23 诺华有限公司 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物
MX362819B (es) * 2013-01-15 2019-02-18 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
JP6338223B2 (ja) 2013-01-15 2018-06-06 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
KR101879919B1 (ko) * 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
IL115305A0 (en) 1994-09-14 1995-12-31 Lundbeck & Co As H Carbamolyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6313247B1 (en) * 1996-06-05 2001-11-06 Wolfgang Lindner Cinchonan based chiral selectors for separation of stereoisomers
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser
NZ517788A (en) * 1999-09-28 2003-11-28 Eisai Co Ltd Quinuclidine compounds and drugs containing the same as the active ingredient
US6479510B2 (en) * 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Also Published As

Publication number Publication date
WO2001085727A1 (en) 2001-11-15
AU6225701A (en) 2001-11-20
NO20025280L (no) 2002-11-04
PE20020221A1 (es) 2002-04-23
CZ20023622A3 (cs) 2003-02-12
ZA200208969B (en) 2003-10-07
PT1282620E (pt) 2004-07-30
US20030166654A1 (en) 2003-09-04
HUP0301866A2 (hu) 2003-09-29
NO20025280D0 (no) 2002-11-04
GB0010955D0 (en) 2000-06-28
BR0110521A (pt) 2003-04-08
US6780861B2 (en) 2004-08-24
ES2218418T3 (es) 2004-11-16
KR20020093974A (ko) 2002-12-16
EP1282620B1 (en) 2004-03-31
EP1282620A1 (en) 2003-02-12
DK1282620T3 (da) 2004-07-19
HK1054223A1 (en) 2003-11-21
RU2002131886A (ru) 2004-04-10
CN1427840A (zh) 2003-07-02
DE60102581T2 (de) 2005-02-03
HK1054223B (en) 2005-03-04
ATE263167T1 (de) 2004-04-15
JP2003532731A (ja) 2003-11-05
IL152417A0 (en) 2003-05-29
SK15612002A3 (sk) 2003-04-01
CA2407972C (en) 2010-03-09
TR200401007T4 (tr) 2004-07-21
JP4898062B2 (ja) 2012-03-14
AU2001262257B2 (en) 2004-11-04
PL357435A1 (en) 2004-07-26
DE60102581D1 (de) 2004-05-06
MXPA02010892A (es) 2003-03-27
NZ522226A (en) 2004-08-27
AR028073A1 (es) 2003-04-23
CA2407972A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
CN1167703C (zh) 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途
AU2001262257A1 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
ES2639196T3 (es) Método para preparar silodosina
US8084487B2 (en) Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof
CN1011784B (zh) 制备抗过敏和抗支气管痉挛药n-二苯甲基二氮杂环烷基烷基n-酰苯胺的方法
JPH0641475B2 (ja) 置換アルファアミノ酸、その製法および医薬
CN1659170A (zh) 噻吩基化合物
CN1183136C (zh) 吲哚并喹唑啉酮
CN1043574C (zh) 具有中枢神经系统活性的杂环胺
CN1156989A (zh) N-取代的氮杂双环庚烷衍生物及其制备方法和应用
CN1255130A (zh) 化合物
CN1146992A (zh) 中间体(r)-3-氨基-5-甲氧基苯并二氢吡喃的制备方法
CN1210262C (zh) 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法
JP2008013558A (ja) 新規ナフタレン化合物、その製造法、およびそれを含有する薬学的組成物
CN100341874C (zh) 异喹啉－3－甲酸酰胺及其药物用途
CN1133288A (zh) 具有1-(芳基链烯基)-4-(芳基甲基)哌嗪结构的新化合物，其制备方法及含这类化合物的药物组合物
CA2015665A1 (fr) Derive d'hydroxyphenethylamine et ses sels, procede de preparation, application a titre de medicaments et utilisation comme outil pharmacologique specifique
JP2001354650A (ja) １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシル酸塩三水和物の調製方法及びそのために有用な中間体
TW201116512A (en) New piperidine compounds, a process for their preparation and pharmaceutical compositions containing them
CN1120042A (zh) 取代1-(7-氯喹啉-4-基)吡唑-3-甲酰胺n-氧化物衍生物，其制备方法及药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040922

Termination date: 20160503

CF01 Termination of patent right due to non-payment of annual fee